Larimar Therapeutics
LRMR
123 hedge funds and large institutions have $421M invested in Larimar Therapeutics in 2024 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 8 closing their positions.
229% more call options, than puts
Call options by funds: $2.83M | Put options by funds: $861K
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
15% more funds holding
Funds holding: 107 → 123 (+16)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.57% less ownership
Funds ownership: 102.39% → 100.81% (-1.6%)
11% less capital invested
Capital invested by funds: $473M → $421M (-$52.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$9.56M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.65M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
+$2.47M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$1.95M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$5.11M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$3.48M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$3.44M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.19M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.08M |
LRMR Hedge Fund Activity: Q3 2024 in Review
123 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q3 2024, worth a combined $421M — down 11% from $473M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LRMR positions and 8 closed out — a net gain of 16 holders — while 41 added to existing stakes and 35 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $9.56M. The largest seller was Stempoint Capital, exiting entirely with an estimated $5.11M sold.
- 123 institutional investors held Larimar Therapeutics (LRMR) as of Q3 2024, up from 107 in Q2 2024.
- Funds reported $421M of Larimar Therapeutics stock for Q3 2024, down 11% quarter-over-quarter.
- 24 funds opened new Larimar Therapeutics positions in Q3 2024 and 8 closed out, a net change of +16 holders.
- The largest Larimar Therapeutics buyer in Q3 2024 was Janus Henderson Group, an estimated $9.56M added.
- The largest Larimar Therapeutics seller in Q3 2024 was Stempoint Capital, an estimated $5.11M sold.
Based on aggregated 13F filings for Q3 2024.